BMY - Bristol-Myers S Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 DGAZ (0%) ROKU (0%) AAPL (%) UGAZ (0%) AAOI (0%) SPY (0%) SNAP (0%) SBUX (0%) RVLV (0%) PINS (0%) NEWR (0%) LYFT (0%) KOPN (0%) KO (0%) KIM (0%) JNPR (0%) FB (0%) ETSY (0%) DIS (0%) DHI (0%) CSIQ (0%) CSCO (0%) BZUN (0%) BIDU (0%) ALB (0%)

Hits 52 Week High

BMY - Bristol-Myers Squibb...

$58.39 0[%]

15 mins delayed data

People also watch : LLY | AZN | JNJ | SNY | ABBV | PFE

+Watchlist

5 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$58.39	Open
Volume	71	Market Cap	94.531B
Yield	0.0283%	Last Dividend	$1.64

Day

52 Week

The Extreme Risks of Trading Your Own Re...	11/12/19
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach tha...

Bristol-Myers' Opdivo/Yervoy sBLA fo...	11/12/19
Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of...

Bristol-Myers Squibb Company Announces E...	11/12/19
Bristol-Myers Squibb Company announced today the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up...

Can This Biotech Improve On Bristol-Myer...	11/11/19
Shares of Nektar Therapeutics popped Monday after the biotech company's Bristol-Myers Squibb-partnered regimen continued to show promise in never-...

Pfizer-Merck KGaA's Bavencio Fails i...	11/11/19
Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patie...

4 Biotech Stocks That Could Keep Beating...	11/11/19
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

Want To Retire Early? Learn the Intellig...	11/11/19
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If y...

Celgene & Acceleron Get FDA Nod for ...	11/11/19
Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.

Nektar Therapeutics Stock Is Rising on T...	11/11/19
The company released clinical data that raised hope about a drug-development program that has encountered manufacturing problems.

Novartis' Generics Unit to Buy Aspen...	11/11/19
Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.

U.S. Food and Drug Administration Accept...	11/11/19
The FDA also granted Opdivo plus Yervoy Breakthrough Therapy Designation for this potential indication

ANALYST RATINGS

6 analyst ratings (Last 6 months)

33.33 %

Strong Buy + Buy

Price Target (PT)

Hold rating	10/23/19
UBS maintains Neutral rating and raises Price Target from $51.00 to $53.00

Buy rating	10/17/19
and announces Price Target of $60.00

Hold rating	10/10/19
and raises Price Target from $49.00 to $50.00

Hold rating	09/03/19
Bank of America maintains Neutral rating and raises Price Target from $46.00 to $49.00

Hold rating	06/13/19
UBS maintains Neutral rating and lowers Price Target from $55.00 to $51.00

Buy rating	05/28/19
Goldman Sachs initiates coverage with Buy rating and announces Price Target of $54.00

EARNINGS

Date	2019-10-31 (BMO)	Est. (EPS/Rev.)	$1.07/ 5.9B
Actual (EPS/Rev.)	$1.17/ $6.01 B	EPS (TTM)	3.48

TRADERS TRACKING $BMY

Service Name	Trader	% Success
Option Superstars	James Catzen	75.00 %	Subscribe
Alpha Swing Trades	Jonathan	69.00 %	Follow
Options Eagle	George	59.00 %	Follow
Options Marc	Marc M	55.00 %	Follow
Best Trading Ideas	Best Trading Ideas	52.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.